Technology | March 30, 2009

Atherotech Unveils New Cardiometabolic Test Panels

March 30, 2009 – At ACC 2009, Atherotech Inc., developer of the VAP Cholesterol Test, debuted new cardiovascular and metabolic testing panels.

Atherotech is adding more than a dozen new tests, including C-Reactive Protein (hsCRP), ApoE genotype and NT-proBNP, for assessment of patients at intermediate to high risk of cardiometabolic diseases. The company is also adding advanced and follow-up cardiovascular disease (CVD) risk profiles.

"We're maximizing the value of our core VAP technology with additional cardiometabolic tests," said Atherotech president Michael Mullen. "This provides physicians and cardiology practices with a single source for the VAP Cholesterol Test plus the new test panels. You get the complete cardiovascular and metabolic view."

The VAP Test, which recently added apoAI (and the apoB/apoAI ratio) to its panel, uses advanced lipid profile testing in the identification of individuals at increased risk of heart disease. The new test panels enable Atherotech to increase its scientific and diagnostic capabilities by offering much more complete cardiometabolic testing.

Steven Margolis, M.D., FAAFP, DABCL, a board-certified lipidologist who currently uses the VAP Test for advanced lipid testing of patients in his Sterling Heights, MI, practice, says the new testing panels add significant benefits for practices such as his.

"It's very convenient for physicians to be able to get these heart disease risk factor tests grouped together and not have to deal with multiple reference labs," Dr. Margolis said. "They're also now offering specialized tests such as apoE genetic testing and NT-proBNP that aren't offered by most other reference laboratories."

The new test panels are available immediately and also include homocysteine, creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D, fibrinogen and insulin. The tests can be ordered individually, or bundled as part of a custom risk profile that may also include the VAP Test.

The VAP Test provides researchers and medical professionals with direct measurement of LDL, HDL and all relevant subclasses, and includes non-HDL, a highly accurate determination of apoB, and emerging risk factors such as Lp(a), remnants and small dense LDL. The VAP (Vertical Auto Profile) Test is reportedly now the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.

For more information: www.atherotech.com, www.thevaptest.com

Related Content

PTSD Alone Does Not Increase Heart Disease Risk in Veterans
News | Cardiac Diagnostics | February 20, 2019
February 20, 2019 — Post-traumatic stress disorder (PTSD) by itself does not explain the...
Hormone Therapy May Increase Cardiovascular Risk During Gender Transition
News | Cardiac Diagnostics | February 18, 2019
Patients receiving hormone therapy as part of their gender-transition treatment had an elevated risk for cardiovascular...
IBM and Broad Institute Launch AI Initiative for Cardiovascular Disease Risk Prediction
News | Cardiac Diagnostics | February 15, 2019
IBM Watson Health and the Broad Institute of MIT and Harvard are launching a research partnership aimed at developing...
Nearly Half of All U.S. Adults Have Cardiovascular Disease
News | Cardiac Diagnostics | January 31, 2019
January 31, 2019 — Nearly half (48 percent, 121.5 million in 2016) of all adults in the United States have some type
Frequent Red Meat Consumption Triples Levels of Chemical Associated With Heart Disease
News | Cardiac Diagnostics | January 23, 2019
Researchers have identified another reason to limit red meat consumption: high levels of a gut-generated chemical...
Plant-Based Diets Benefit Athletes' Heart Health, Endurance, Recovery
News | Cardiac Diagnostics | January 21, 2019
Meat-free athletes have already proven the performance-boosting power of a plant-based diet. Now, “Plant-Based Diets...
Sedentary Lifestyle Cancels Out Heart Benefits of Normal Weight
News | Cardiac Diagnostics | January 09, 2019
January 9, 2019 — Researchers at the University of Florida have found that low levels of physical activity can put he
Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
Overlay Init